Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer
R3 emerges as a promising VEGFR2-targeted lead for further breast cancer drug development and structure-activity relationship analysis indicated that meta and para chloro substitutions enhance binding and activity, while ortho substitution reduces affinity due to steric effects.